{"analyses":[{"ciLowerLimit":"0.595","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.038","groupDescription":"Teff high-WT","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0894","paramType":"Hazard Ratio (HR)","paramValue":"0.786","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.626","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.061","groupDescription":"Teff high","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.1276","paramType":"Hazard Ratio (HR)","paramValue":"0.815","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.733","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.011","groupDescription":"ITT","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0681","paramType":"Hazard Ratio (HR)","paramValue":"0.861","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.6","upperLimit":"26.3","value":"21.3"},{"groupId":"OG001","lowerLimit":"11.2","upperLimit":"22.3","value":"16.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"130"}],"units":"Participants"}],"title":"Teff-high WT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.1","upperLimit":"26.0","value":"21.0"},{"groupId":"OG001","lowerLimit":"11.4","upperLimit":"21.6","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Teff-high Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.3","upperLimit":"21.5","value":"19.0"},{"groupId":"OG001","lowerLimit":"13.4","upperLimit":"17.1","value":"15.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"402"},{"groupId":"OG001","value":"400"}],"units":"Participants"}],"title":"ITT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"402"},{"groupId":"OG001","value":"400"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.","id":"OG001","title":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"Teff-high WT population, defined as Teff-high population excluding patients with an activating EGFR mutation or ALK translocation. Teff-high population, defined as patients in the ITT population with Teff signature expression \\>=-1.91. ITT population is defined as all randomized patients, regardless of receipt of the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Baseline until death (up approximately 53 months)","title":"OS in Arm A Versus Arm C in Teff High-WT Population, Teff High Population, and ITT Population","type":"SECONDARY","unitOfMeasure":"Months"}